|
Sunesis Pharmaceuticals announced that it has granted Carmot Therapeutics, Inc., a privately-held biotechnology company, an exclusive license to its proprietary Fragment-Based Lead Discovery (FBLD) technology
SOUTH SAN FRANCISCO, CA, USA | February 08, 2010 | Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it has granted Carmot Therapeutics, Inc., a privately-held biotechnology company, an exclusive license to its proprietary Fragment-Based Lead Discovery (FBLD) technology. Carmot will use the FBLD technology, called "Chemotype Evolution," for identifying promising drug candidates in a broad range of therapeutic areas, including inflammatory, metabolic, and neurodegenerative diseases. Sunesis retains full rights to the technology for use in its future internal discovery efforts. Terms of the agreement were not disclosed.
"This agreement reflects our strategy to leverage the value of our non-core assets while focusing our resources on advancing voreloxin into a pivotal Phase 3 trial in acute myeloid leukemia later this year," stated Eric Bjerkholt, Senior Vice President, Corporate Development & Finance of Sunesis. "The FBLD discovery technology has the potential to generate compounds which may not be identified through traditional means of drug discovery. We are pleased that we can capitalize on Carmot's use of the technology to advance its research activities while at the same time retain full rights to use the platform technology for our own internal research applications."
"We believe that Chemotype Evolution has the potential to transform drug discovery and accelerate our efforts to identify novel drug candidates for challenging disease targets," stated Stig Hansen, Ph.D. and Daniel Erlanson, Ph.D., co-founders of Carmot. Carmot has recently received grants from the National Science Foundation and the Michael J. Fox Foundation for Parkinson's Research.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis, please visit http://www.sunesis.com.
SOURCE: Sunesis Pharmaceuticals |
